Navigation Links
European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis
Date:12/4/2009

WASHINGTON, Dec. 4 /PRNewswire-USNewswire/ -- A simple, inexpensive computer tool that measures volume changes in the size of suspicious nodules in the lungs picked up by a CT scanner can rule out non-cancerous ones with almost perfect accuracy and enable doctors to diagnose true cancers with fewer, less expensive and less invasive tests.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO)

The new diagnostic guidelines are described in a paper published yesterday in the New England Journal of Medicine on the progress of large European lung cancer CT screening trial (NELSON) launched in the Netherlands and Belgium in 2004.

"For years, those of us on the front lines of managing this extremely lethal disease have seen firsthand the impact early detection can have on the patients we serve and the people who love and care for them," said Dr. Michael Vincent Smith, an Atlanta-Area thoracic surgeon, President-Elect of the Atlanta Medical Association and founder of the first lung cancer early detection program in the state of Georgia.

"This carefully executed trial in over 7000 screening participant provides insight into management modalities to assist practicing physicians who diagnose and treat lung cancers," he said.

Advances in imaging technology have enabled scanners to detect suspicious nodules in the lung smaller than a grain of rice, but how to determine which ones are cancerous without further expensive or invasive and potentially dangerous testing is the question.

NELSON collaborators addressed the issue by using volume measurement and volume doubling time as the criteria for further action, a concept first proposed by CT diagnostic pioneers with the International Early Lung Cancer Action Program.

The refined protocol can rule out non-cancer nodules with 99.9% accuracy and at the same time reduce the number of tests required to confirm cancer in a malignant nodule. In the NELSON trial, only 1% of positive cancers required a biopsy for confirmation.

"As a specialist treating lung cancer in a region of the country with some of the highest death rates, we welcome the widespread dissemination of studies like the Nelson Trial," says Dr. Smith.

"Studies like this lend greater credibility to our belief that patients enrolled in well-designed lung cancer early detection research programs based on high resolution Computed Tomography scanning will lead to generating conclusive proof of significant lung cancer mortality reduction."

The NELSON trial will continue to examine the mortality impact of CT screening by comparing the number of lung cancer deaths that occur among the 7557 people getting scans with a similar number of people who do not. In the United States, the National Lung Screening Trial is also looking at mortality differences between those screened with a chest x-ray and those screened with a CT scan.

Both trials are expected to be completed within the next three to five years.

SOURCE Lung Cancer Alliance


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):